Chronic lymphocytic leukemia: A paradigm of innate immune cross-tolerance

Journal of Immunology

Volumn 194, Issue 2, 2015, Pages 719-727

  Jurado Camino, Teresa ^a   Córdoba, Raúl ^a,b   Esteban Burgos, Laura ^a   Hernández Jiménez, Enrique ^a   Toledano, Victor ^a   Hernandez Rivas, Jose Angel ^c   Ruiz Sainz, Elena ^d   Cobo, Teresa ^e   Siliceo, María ^a   De Diego, Rebeca Perez ^a   Belda, Cristobal ^f   Cubillos Zapata, Carolina ^a   López Collazo, Eduardo ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^d Aranjuez   (Spain)

^e Hospital del Sureste   (Spain)

^f Grupo HM Hospitales   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MESSENGER RNA; MICRORNA 146A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; CYTOKINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN; MICRORNA; MIRN146 MICRORNA, HUMAN;

AGED; ANTIGEN PRESENTATION; ARTICLE; CELL ISOLATION; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; CROSS TOLERANCE; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; INTRACELLULAR SIGNALING; IRAK1 GENE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PHAGOCYTOSIS; RNA ANALYSIS; TNF ALPHA GENE; TRAF6 GENE; UPREGULATION; CLINICAL TRIAL; GENE EXPRESSION REGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CYTOKINES; DOWN-REGULATION; ENDOTOXINS; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICRORNAS; MIDDLE AGED; MONOCYTES; T-LYMPHOCYTES; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 84920427986     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402272     Document Type: Article

References (59)

1. Siegel, R., J. Ma, Z. Zou, and A. Jemal. 2014. Cancer statistics, 2014. CA Cancer J. Clin. 64: 9-29.
2. Maurer, C., and M. Hallek. 2013. [Chronic lymphocytic leukemia]. Dtsch. Med. Wochenschr. 138: 2153-2166.
3. Foa, R., D. Catovsky, M. Brozovic, G. Marsh, T. Ooyirilangkumaran, M. Cherchi, and D. A. Galton. 1979. Clinical staging and immunological findings in chronic lymphocytic leukemia. Cancer 44: 483-487.
4. Ravandi, F., and S. O'Brien. 2006. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol. Immunother. 55: 197-209.
5. Molica, S., D. Levato, and L. Levato. 1993. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 78: 374-377.
6. Morrison, V. A. 1998. The infectious complications of chronic lymphocytic leukemia. Semin. Oncol. 25: 98-106.
7. Itälä, M., H. Helenius, J. Nikoskelainen, and K. Remes. 1992. Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur. J. Haematol. 48: 266-270.
8. Tsiodras, S., G. Samonis, M. J. Keating, and D. P. Kontoyiannis. 2000. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin. Proc. 75: 1039-1054.
9. Molica, S. 1994. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk. Lymphoma 13: 203-214.
10. Rozman, C., and E. Montserrat. 1995. Chronic lymphocytic leukemia. N. Engl. J. Med. 333: 1052-1057.
11. Ahmed, S., A. K. Siddiqui, L. Rossoff, C. P. Sison, and K. R. Rai. 2003. Pulmonary complications in chronic lymphocytic leukemia. Cancer 98: 1912-1917.
12. Rai, K. R., and E. Montserrat. 1987. Prognostic factors in chronic lymphocytic leukemia. Semin. Hematol. 24: 252-256.
13. Biswas, S. K., and E. Lopez-Collazo. 2009. Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol. 30: 475-487.
14. López-Collazo, E., and C. del Fresno. 2013. Pathophysiology of endotoxin tolerance: mechanisms and clinical consequences. Crit. Care 17: 242.
15. del Fresno, C., F. García-Rio, V. Gómez-Piña, A. Soares-Schanoski, I. Fernández-Ruíz, T. Jurado, T. Kajiji, C. Shu, E. Marín, A. Gutierrez del Arroyo, et al. 2009. Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J. Immunol. 182: 6494-6507.
16. Soares-Schanoski, A., T. Jurado, R. Córdoba, M. Siliceo, C. D. Fresno, V. Gómez-Piña, V. Toledano, M. T. Vallejo-Cremades, S. Alfonso-Iñiguez, A. Carballo-Palos, et al. 2012. Impaired antigen presentation and potent phagocytic activity identifying tumor-tolerant human monocytes. Biochem. Biophys. Res. Commun. 423: 331-337.
17. Mantovani, A., and A. Sica. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22: 231-237.
18. Pena, O. M., J. Pistolic, D. Raj, C. D. Fjell, and R. E. Hancock. 2011. Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J. Immunol. 186: 7243-7254.
19. Mantovani, A., A. Sica, P. Allavena, C. Garlanda, and M. Locati. 2009. Tumorassociated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 70: 325-330.
20. del Fresno, C., K. Otero, L. Gómez-García, M. C. González-León, L. Soler- Ranger, P. Fuentes-Prior, P. Escoll, R. Baos, L. Caveda, F. García, et al. 2005. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J. Immunol. 174: 3032-3040.
21. Campo, E., S. H. Swerdlow, N. L. Harris, S. Pileri, H. Stein, and E. S. Jaffe. 2011. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117: 5019-5032.
22. Janssens, S., and R. Beyaert. 2003. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol. Cell 11: 293-302.
23. Hernández-Jiménez, E., R. Del Campo, V. Toledano, M. T. Vallejo-Cremades, A. Muñoz, C. Largo, F. Arnalich, F. García-Rio, C. Cubillos-Zapata, and E. López- Collazo. 2013. Biofilm vs. planktonic bacterial mode of growth: which do human macrophages prefer? Biochem. Biophys. Res. Commun. 441: 947-952.
24. Hernandez-Fuentes, M. P., A. N. Warrens, and R. I. Lechler. 2003. Immunologic monitoring. Immunol. Rev. 196: 247-264.
25. Escoll, P., C. del Fresno, L. García, G. Vallés, M. J. Lendínez, F. Arnalich, and E. López-Collazo. 2003. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem. Biophys. Res. Commun. 311: 465-472.
26. del Fresno, C., V. Gómez-Piña, V. Lores, A. Soares-Schanoski, I. Fernández- Ruiz, B. Rojo, R. Alvarez-Sala, E. Caballero-Garrido, F. García, T. Veliz, et al. 2008. Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS ONE 3: e2667.
27. Gómez-Piña, V., A. Soares-Schanoski, A. Rodríguez-Rojas, C. Del Fresno, F. García, M. T. Vallejo-Cremades, I. Fernández-Ruiz, F. Arnalich, P. Fuentes-Prior, and E. López-Collazo. 2007. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J. Immunol. 179: 4065-4073.
28. Livak, K. J., and T. D. Schmittgen. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) Method. Methods 25: 402-408.
29. Maffei, R., J. Bulgarelli, S. Fiorcari, L. Bertoncelli, S. Martinelli, C. Guarnotta, I. Castelli, S. Deaglio, G. Debbia, S. De Biasi, et al. 2013. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 98: 1115-1123.
30. Grage-Griebenow, E., H. D. Flad, M. Ernst, M. Bzowska, J. Skrzeczyñska, and J. Pryjma. 2000. Human MO subsets as defined by expression of CD64 and CD16 differ in phagocytic activity and generation of oxygen intermediates. Immunobiology 202: 42-50.
31. Ioan-Facsinay, A., S. J. de Kimpe, S. M. Hellwig, P. L. van Lent, F. M. Hofhuis, H. H. van Ojik, C. Sedlik, S. A. da Silveira, J. Gerber, Y. F. de Jong, et al. 2002. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16: 391-402.
32. Adams, A. B., T. C. Pearson, and C. P. Larsen. 2003. Heterologous immunity: An overlooked barrier to tolerance. Immunol. Rev. 196: 147-160.
33. Sironen, R. K., M. Tammi, R. Tammi, P. K. Auvinen, M. Anttila, and V. M. Kosma. 2011. Hyaluronan in human malignancies. Exp. Cell Res. 317: 383-391.
34. Yabushita, H., M. Noguchi, T. Kishida, K. Fusano, Y. Noguchi, N. Itano, K. Kimata, and M. Noguchi. 2004. Hyaluronan synthase expression in ovarian cancer. Oncol. Rep. 12: 739-743.
35. Lin, W. W., and S. L. Hsieh. 2011. Decoy receptor 3: A pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem. Pharmacol. 81: 838-847.
36. Sheikh, M. S., and A. J. Fornace Jr. 2000. Death and decoy receptors and p53- mediated apoptosis. Leukemia 14: 1509-1513.
37. Toole, B. P., T. N.Wight, and M. I. Tammi. 2002. Hyaluronan-cell interactions in cancer and vascular disease. J. Biol. Chem. 277: 4593-4596.
38. O'Neill, L. A., and A. G. Bowie. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7: 353-364.
39. Dobrovolskaia, M. A., and S. N. Vogel. 2002. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 4: 903-914.
40. Ali, S., and D. A. Mann. 2004. Signal transduction via the NF-kappaB pathway: A targeted treatment modality for infection, inflammation and repair. Cell Biochem. Funct. 22: 67-79.
41. Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140: 821-832.
42. Brocker, C., D. Thompson, A. Matsumoto, D. W. Nebert, and V. Vasiliou. 2010. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum. Genomics 5: 30-55.
43. Dinarello, C. A. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117: 3720-3732.
44. Suzuki, N., S. Suzuki, G. S. Duncan, D. G. Millar, T. Wada, C. Mirtsos, H. Takada, A. Wakeham, A. Itie, S. Li, et al. 2002. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416: 750-756.
45. Li, C. H., J. H. Wang, and H. P. Redmond. 2006. Bacterial lipoproteininduced self-tolerance and cross-tolerance to LPS are associated with reduced IRAK-1 expression and MyD88-IRAK complex formation. J. Leukoc. Biol. 79: 867-875.
46. Fan, H., and J. A. Cook. 2004. Molecular mechanisms of endotoxin tolerance. J. Endotoxin Res. 10: 71-84.
47. Biswas, S. K., and V. Tergaonkar. 2007. Myeloid differentiation factor 88-independent Toll-like receptor pathway: Sustaining inflammation or promoting tolerance? Int. J. Biochem. Cell Biol. 39: 1582-1592.
48. Taganov, K. D., M. P. Boldin, K. J. Chang, and D. Baltimore. 2006. NF-kappaBdependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 103: 12481-12486.
49. Perry, M. M., A. E. Williams, E. Tsitsiou, H. M. Larner-Svensson, and M. A. Lindsay. 2009. Divergent intracellular pathways regulate interleukin- 1beta-induced miR-146a and miR-146b expression and chemokine release in human alveolar epithelial cells. FEBS Lett. 583: 3349-3355.
50. Nahid, M. A., M. Satoh, and E. K. Chan. 2011. Mechanistic role of microRNA- 146a in endotoxin-induced differential cross-regulation of TLR signaling. J. Immunol. 186: 1723-1734.
51. Nahid, M. A., K. M. Pauley, M. Satoh, and E. K. Chan. 2009. miR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY. J. Biol. Chem. 284: 34590-34599.
52. Li, L., S. Cousart, J. Hu, and C. E. McCall. 2000. Characterization of interleukin- 1 receptor-associated kinase in normal and endotoxin-tolerant cells. J. Biol. Chem. 275: 23340-23345.
53. Yang, K., Y. S. He, X. Q.Wang, L. Lu, Q. J. Chen, J. Liu, Z. Sun, and W. F. Shen. 2011. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 585: 854-860.
54. Hou, J., P. Wang, L. Lin, X. Liu, F. Ma, H. An, Z. Wang, and X. Cao. 2009. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J. Immunol. 183: 2150- 2158.
55. Stacchini, A., M. Aragno, A. Vallario, A. Alfarano, P. Circosta, D. Gottardi, A. Faldella, G. Rege-Cambrin, U. Thunberg, K. Nilsson, and F. Caligaris-Cappio. 1999. MEC1 and MEC2: Two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk. Res. 23: 127-136.
56. Wolk, K., W. D. Döcke, V. von Baehr, H. D. Volk, and R. Sabat. 2000. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96: 218-223.
57. del Campo, R., E. Martínez, C. del Fresno, R. Alenda, V. Gómez-Piña, I. Fernández-Ruíz, M. Siliceo, T. Jurado, V. Toledano, F. Arnalich, et al. 2011. Translocated LPS might cause endotoxin tolerance in circulating monocytes of cystic fibrosis patients. PLoS ONE 6: e29577.
58. Fernández-Ruiz, I., F. Arnalich, C. Cubillos-Zapata, E. Hernández-Jiménez, R. Moreno-González, V. Toledano, M. Fernández-Velasco, M. T. Vallejo-Cremades, L. Esteban-Burgos, R. P. de Diego, et al. 2014. Mitochondrial DAMPs induce endotoxin tolerance in human monocytes: An observation in patients with myocardial infarction. PLoS ONE 9: e95073.
59. Shao, Y., J. Li, Y. Cai, Y. Xie, G. Ma, Y. Li, Y. Chen, G. Liu, B. Zhao, L. Cui, and K. Li. 2014. The functional polymorphisms of miR-146a are associated with susceptibility to severe sepsis in the Chinese population. Mediators Inflamm. 2014: 916202.